A Pragmatic Trial to Evaluate a Guideline Based Colony Stimulating Factor Standing Order Intervention and to Determine the Effectiveness of Colony Stimulating Factor Use as Prophylaxis for Patients Receiving Chemotherapy with Intermediate Risk for Febrile Neutropenia Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER)
TrACER: Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER) for Patients Receiving Chemotherapy
Sponsor: Southwest Oncology Group
Enrolling: Male and Female Patients
IRB Number: AAAR0311
U.S. Govt. ID: NCT02728596
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: This randomized clinical trial studies prophylactic colony stimulating factor management in patients with breast, colorectal or non-small cell lung cancer receiving chemotherapy and with risk of developing febrile neutropenia. Patients receiving chemotherapy may develop febrile neutropenia. Febrile neutropenia is a condition that involves fever and a low number of neutrophils (a type of white blood cell) in the blood. Febrile neutropenia increases the risk of infection. Colony stimulating factors are medications sometimes given to patients receiving chemotherapy to prevent febrile neutropenia. Colony stimulating factors are given to patients based on guidelines. Some clinics have an automated system that helps doctors decide when to prescribe them when there is a high risk of developing febrile neutropenia. Gathering information about the use of an automated system to prescribe prophylactic colony stimulating factor may help doctors use colony stimulating factor when it is needed.
This study is closed
Dawn Hershman, MD
Do You Qualify?
Have you been diagnosed with breast cancer? Yes No
Have you received systemic therapy (chemotherapy, immunotherapy, biologic therapy, or combination ) in the past 180 days? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator